PORTLAND, ME--(Marketwire - August 5, 2010) - ImmuCell Corporation (
For the three-month period ended June 30, 2010, product sales increased by 8%, or $77,000, to $1,078,000 in comparison to the same period in 2009. For the six-month period ended June 30, 2010, product sales decreased by 3%, or $71,000, to $2,389,000 in comparison to the same period in 2009. Year-to-date domestic sales increased by approximately 8%, but this increase was more than offset by a decline in foreign sales. As of June 30, 2009, the backlog of First Defense® orders aggregated $287,000. There was no backlog as of June 30, 2010.
"In this economy and specifically in this dairy market with low milk prices and high feed costs, we are fortunate to see an 8% increase in our domestic product sales," commented Michael F. Brigham, President and CEO. "We believe that the level of domestic sales of First Defense® that we are seeing, at a time when our customers are taking cost-cutting measures, indicates the value of this technology to producers."
The loss before income taxes was $(37,000) during the three-month period ended June 30, 2010 in comparison to a loss before income taxes of $(283,000) during the same period in 2009. The net loss was $(6,000), or less than $(0.01) per share, during the three-month period ended June 30, 2010 in comparison to a net loss of $(148,000), or $(0.05) per share, during the same period in 2009. The loss before income taxes was $(102,000) during the six-month period ended June 30, 2010 in comparison to a loss before income taxes of $(319,000) during the same period in 2009. The net loss was $(60,000), or $(0.02) per share, during the six-month period ended June 30, 2010 in comparison to a net loss of $(182,000), or $(0.06) per share, during the same period in 2009.
Cash, cash equivalents and short-term investments decreased by 8%, or $369,000, to $4,217,000 at June 30, 2010 as compared to $4,585,000 at December 31, 2009. Stockholders' equity decreased by less than 1%, or $45,000, to $9,577,000 at June 30, 2010 as compared to $9,622,000 at December 31, 2009. The Company had 2,971,000 shares of common stock outstanding as of June 30, 2010.
Other news/milestones:
In July, we entered into a Development and Manufacturing Agreement with Lonza Sales Ltd. of Basel, Switzerland. This contract covers terms under which we will pay Lonza to exclusively i) adapt our proprietary Nisin manufacturing process at commercial scale and ii) manufacture the Nisin Active Pharmaceutical Ingredient for use in Mast Out®, which is subject to approval by the U.S. Food and Drug Administration before any sales can be made. Financial obligations of the Company to Lonza are staged on a commitment-by-commitment basis, as the intended development process is conducted. Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries.
| (Unaudited) Three Months Ended June 30, |
(Unaudited) Six Months Ended June 30, |
||||||||||||||
| (In thousands, except per share amounts) | 2010 | 2009 | 2010 | 2009 | |||||||||||
| Revenues: | |||||||||||||||
| Product Sales | $ | 1,078 | $ | 1,000 | $ | 2,389 | $ | 2,461 | |||||||
| Other Revenues | 1 | 1 | 2 | 2 | |||||||||||
| Total Revenues | 1,079 | 1,001 | 2,391 | 2,463 | |||||||||||
| Cost and expenses: | |||||||||||||||
| Product costs | 459 | 513 | 1,032 | 1,253 | |||||||||||
| Product development expenses | 333 | 489 | 739 | 921 | |||||||||||
| Sales, marketing and administrative expenses | 333 | 315 | 741 | 677 | |||||||||||
| Total costs and expenses | 1,125 | 1,317 | 2,512 | 2,851 | |||||||||||
| Net operating loss | (46 | ) | (316 | ) | (121 | ) | (388 | ) | |||||||
| Interest and other income | 9 | 33 | 19 | 69 | |||||||||||
| Loss before income taxes | (37 | ) | (283 | ) | (102 | ) | (319 | ) | |||||||
| Income tax benefit | (31 | ) | (135 | ) | (42 | ) | (137 | ) | |||||||
| Net loss | $ | (6 | ) | $ | (148 | ) | $ | (60 | ) | $ | (182 | ) | |||
| Net loss per common share: | |||||||||||||||
| Basic | $ | (0.00 | ) | $ | (0.05 | ) | $ | (0.02 | ) | $ | (0.06 | ) | |||
| Diluted | $ | (0.00 | ) | $ | (0.05 | ) | $ | (0.02 | ) | $ | (0.06 | ) | |||
| Weighted average common shares outstanding: | |||||||||||||||
| Basic | 2,971 | 2,971 | 2,971 | 2,947 | |||||||||||
| Diluted | 2,971 | 2,971 | 2,971 | 2,947 | |||||||||||
| (In thousands) | At June 30, 2010 | At December 31, 2009 | |||
| Cash, cash equivalents and short-term investments | $ | 4,217 | $ | 4,585 | |
| Total assets | 9,905 | 9,985 | |||
| Net working capital | 5,962 | 5,944 | |||
| Stockholders' equity | $ | 9,577 | $ | 9,622 | |
Our purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site (http://www.immucell.com).
Contact Information:
Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106